IE56814B1 - Mitomycin analogs - Google Patents

Mitomycin analogs

Info

Publication number
IE56814B1
IE56814B1 IE272/84A IE27284A IE56814B1 IE 56814 B1 IE56814 B1 IE 56814B1 IE 272/84 A IE272/84 A IE 272/84A IE 27284 A IE27284 A IE 27284A IE 56814 B1 IE56814 B1 IE 56814B1
Authority
IE
Ireland
Prior art keywords
lower alkyl
hydroxymethyl
indole
pyrrolo
azirino
Prior art date
Application number
IE272/84A
Other versions
IE840272L (en
Original Assignee
University Patents Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Patents Inc filed Critical University Patents Inc
Publication of IE840272L publication Critical patent/IE840272L/en
Publication of IE56814B1 publication Critical patent/IE56814B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Mitomycin derivatives useful for treatment of neoplastic disease states in animals have the formula IIIa, wherein: Y is hydrogen or lower alkyl; and Z is an hydroxy substituted 1-pyrrolidinyl radical, or a lower alkyl substituted piperidyl radical, or a 1-piperazinyl radical or an acetamino, acetyl, carbamido, cyano, carboxy lower alkylamino, di-lower alkoxy, nitro, sulfamyl, or lower alkyl substituted anilino radical, or a radical of the formula, wherein R is hydrogen or lower alkyl and R<1> is a nitrogen containing heterocyclic radial selected from amino substituted triazolyl, lower alkyl substituted isothiazolyl, benzothiazolyl, and nitro and halo substituted derivatives of benzothiazolyl, or R<1> is a substituted lower alkyl radical selected from amino lower alkyl, lower alkylamino lower alkyl, hydroxy lower alkylamino lower alkyl, hydroxy lower alkoxy lower alkyl, imidazolyl lower alkyl, nitro substituted imidazolyl lower alkyl, mono- and di-hydroxy phenyl lower alkyl, nitro substituted pyridylamino lower alkyl, piperazinyl lower alkyl, and pyridyl ethyl.

Description

The present invention relates generally to antibiotic mitosane compounds and to their use in the treatment of neoplastic disease states in animals.
The disclosures of U.S. Letters Patent No. 5 4,268,676; co-pending U.S. Patent Application Serial No. 206,529 filed November 13, 1980; and Patent Specification No.5 may provide essential and nonessential material relating to the present invention.
Briefly summarized, said U.S. Patent No. 4,268,676 and cc-pending application Serial No. 206,529 set forth a statement of the background of the ongoing search in the art for new and useful compounds which are structurally related to the mitomycins, which possess antibiotic activity, which have low toxicity and which display a substantial degree of antitumor activity in animals. More particularly, they disclose new compounds of the formula I, wherein; Y is hydrogen or lower alkyl; and X is a thiazolamino radical, a furfurylamino radical or a radical of the formula, ** in which R, R and R* are the same or different and selected from the group consisting of hydrogen and 3 lower alkyl, and R is selected from the group consisting of lower alkenyl, halo-lower alkenyl, lower alkynyl, lower alkoxycarbonyl, thienyl, formamyl, tetrahydrofuryl and benzene sulfonamide.
Said U.S. patent and pending application also disclose novel methods for treatment of neoplastic disease states in animals, which methods comprise administering a therapeutically effective amount of a compound of the formula, Xa, wherein: Y is hydrogen or lower alkyl? and Z 15 is a thiazolamino radical, a furfurylamino radical, a cyclopropylamino radical, a pyridylamino radical, or a radical of the formula® 6 in which R , R , and R are the same or different and selected from the group consisting of hydrogen and lower alkyl, and R7 is selected from the group consisting of lower alkenyl, halo-lower alkenyl, lower alkynyl, lower alkoxycarbonyl, halo-lower alkyl, hydroxy-lower alkyl, pyridyl, thienyl, formamyl, tetrahydrofuryl, benzyl, and benzene sulfonamide.
Patent Specification No. 52 9^6 * also discloses compounds with a substantial degree of antitumor activity in animals of the following formula Ila, wherein: Y is hydrogen or lower alkyl; and Z is a lower alkoxy substituted quinolinylamino radical, a cyano substituted pyrazolylamino radical or a monoor di-lower alkyl substituted thiazolamino radical, or a nitrogen-containing heterocyclic radical selected from the group consisting of 1-pyrrolinyl, 1indolinyl, N-thiazolidinyl, N-morpholinyl, 1-piperazinyl, and N-thiomorpholinyl radicals, or a cyano, phenyl, carboxamido or lower alkoxycarbonyl substituted 1-aziridinyl radical, or a lower alkyl, formyl or acetyIphenyl substituted 1-piperazinyl radical, or an hydroxy or piperidyl substituted 1-piperidyl radical, or a lower alkoxy, amino or halo substituted pyridylamino radical, or a carboxamido, mercapto or methylenedioxy substituted anilino radical, or R I a radical of the formula, -N-R' wherein R is hydrogen or lower alkyl and R* is a nitrogen-containing heterocyclic radical selected from the group consisting of quinuclidinyl, pyrazolyl, 1-triazolyl, isoquinolinyl, indazolyl, benzoxazolyl, thiadiazolyl and benzothiadiazolyl, and lower alkyl and halo substituted derivatives thereof, or a butyrolactonyl radical, or an adamantyl radical, or a mono-lower alkoxy substituted phenyl radical, or a substituted lower alkyl radical selected from the group consisting of mercapto lower alkyl, carboxy lower alkyl, mono-, di- and tri-lower alkoxy lower alkyl, lower alkyl thio lower alkyl and lower alkoxyearbonyl substituted derivatives thereof, cyano lower alkyl, mono-, di- and tri-lower alkoxy phenyl lower alkyl, phenyl cyclo lower alkyl, 1-pyrrolidinyl lower alkyl, N-lower alkyl pyrrolidinyl lower alkyl, Nmorpholinyl lower alkyl, and lower dialkylamino lower alkyl.
Also pertinent to the background of the present invention are the following references; Cosulich, et al., U.S. Patent No. 3,332,944; Matsui, et al., U.S. Patent No. 3,410,867; Nakano, et al, U.S. Patent No. 4,231,936; Matsui, et al., U.S. Patent No. 3,429,894; Remers, U.S. Patent No. 4,268,676; Matsui, et al., U.S.
Patent No. 3,450,705; Matsui, et al., U.S. Patent No. 3,514,452; and Xmai, et al., Gann, 71, pp. 560-562 (1980).
According to the present invention, there are provided novel compounds of the formula, III, wherein: Y is hydrogen or lower alkyl? and X is an hydroxy substituted 1-pyrrolidinyl radical, or a lower alkyl substituted piperidyl radical, or an acetamino, acetyl, carbamide, cyano, carboxy lower alkylamino, di-lower alkoxy, nitro, or sulfamoyl substituted anilino radical, or R a radical of the formula, -N-R1 wherein R is hydrogen or lower alkyl and R1 is a nitrogen containing heterocyclic radical selected from amino substituted triazolyl, lower alkyl substituted isothiazolyl, benzothiazolyl, and nitro and halo substituted derivatives of benzothiazolyl, or R1 is a substituted lower alkyl radical selected from amino lower alkyl, lower alkylamino lower alkyl, hydroxy lower alkylamino lower alkyl, hydroxy lower alkoxy lower alkyl, imidazolyl lower alkyl, nitro substituted imidazolyl lower alkyl, ri mono- and di-hydroxy phenyl lower alkyl, nitro substituted pyridylamino lower alkyl, and piperazinyl lower alkyl.
Also provided according to the invention is a substance for use in the preparation of a medicament for treatment of a neoplastic disease state in an animal, said substance comprising a therapeutically effective amount of a compound of the formula, Ilia, is or or Ilia wherein: Y is hydrogen or lower alkyl; and Z an hydroxy substituted 1-pyrrolidinyl radical, a lower alkyl substituted piperidyl radical, acetyl, carbamido, an acetamino, cyano, carboxy lower alkylamino, dilower alkoxy, nitro, sulfamoyl, or lower alkyl substituted anilino radical, or R a radical of the formula® -N-R3, wherein R is hydrogen or lower alkyl and is a nitrogen containing heterocyclic radical selected from amino substituted triazolyl, lower alkyl substituted isothiazolyl, benzo25 thiazolyl, and nitro and halo substituted derivatives of benzothiazolyl, or R1 a substituted lower alkyl radical selected from amino lower alkyl, lower alkylamino lower alkyl, hydroxy lower alkylamino lower alkyl, hydroxy lower alkoxy lower alkyl, imidazolyl lower alkyl, nitro substituted imidazolyl lower alkyl, mono- and di-hydroxy phenyl lower alkyl, nitro substituted pyridylamino lower alkyl, piperazinyl lower alkyl, and 2-(pyridyl)ethyl.
Unless otherwise indicated, the term lower, applied to alkyl radicals shall designate such straight . or branched chain radicals as to include from one to six carbon atoms. By way of illustration, lower alkyl shall mean and include, for exanple, methyl, ethyl, propyl, butyl, pentyl and hexyl radicals as well as isopropyl radicals, and t-butyl radicals. Similarly, lower as applied to alkoxy shall designate a radical having one to six carbon atoms.
It will be apparent that the compounds of formula III are all comprehended by the specifications of formula Ilia. Put another way, all the novel antibiotic mitomycin derivatives of formula III are useful in practice of the novel antineoplastic therapeutic methods which involve administration of compounds of formula I IIa.
Mitomycin derivatives of the invention are prepared by the reaction of mitomycin A with the appropriately selected amine compounds. The N-alkylmitomycin (e.g., N-methylmitomycin) derivatives are similarly prepared by the reaction of a selected amine with Nalkylmitomycin A prepared from mitomycin C, e.g., according to the methods generally disclosed in Cheng, et al., J.Med.Chem., 20, No. 6, 767-770 (1977), The preparative reactions generally yield the desired product as a crystalline solid which is readily soluble b in alcohol.
Substances of the invention are used in a medicament for a method in which the administration of effective amounts of one or more < of the compounds of formula Ilia, as an active ingredient, together with desired pharmaceutically acceptable diluents, adjuvants and carriers, to an animal suffering from a neoplastic disease state is carried out. Unit dosage forms of oorapounds administered according to . the methods described above may range from 0.001 to 5.0 mg and preferably from 0.004 to 1.0 mg, of the compounds. Such unit dosage quantities may be given to provide a daily dosage of from O.l to 100 mg per kg, and preferably from 0.2 to 51.2 mg per kg, of body weight of the animal treated.
Parenteral administration, and especially intraperitoneal administration, is the preferred route for practice of the above methods.
Other aspects and advantages of the present invention will become apparent upon consideration of the following description.
The following Examples 1 through 32, describing preparation of certain presently preferred compounds according to the invention, are for illustrative purposes only and are not to be construed as limiting the invention. Unless otherwise indicated, all reactions were carried out at room temperature (20*C), without added heat.
Unless otherwise indicated, all thin layer chromatographic (TLC) procedures employed to check the progress of reactions involved the use of a pre-coated silicagel plate and a mixture of methanol and chloroform (2:8 by volume) as a developing solvent.
Example 1 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8a-methoxy5-methyl-6-(3-hydroxy-l-pyrrolidlnyl) -azirino[2 *, 31:3/4] pyrrolo[1,2-a]indole-4,7-dione carbamate A solution of mitomycin A (50 mg) in 6 ml of anhydrous methanol was treated with 3-pyrrolidinol (13 mg) under nitrogen at room temperature. VThen thinlayer chromatography on silica gel (2:8 methanolchloroform as solvent) showed that starting material no longer was present, the mixture was filtered and evaporated under reduced pressure. The residue was purified by preparative thin-layer chromatography using the same solvent system. This procedure gave 23 mg (40% yield) of the desired product having a melting point of 82®85°C (decomposition) and providing the following analysis: NMR (DMSO-d,, TS): '6' values in ppm. - o Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 1.6-2.2 (m,2), 2.8-3.1 (broad s,5) and 4.0-4.3 (m,l).
Example 2 1,la,2,8,8a,8b-Hexahvdro-8-(hydroxymethyl)-8a-methoxy5-methy 1-6- (3-methyIpiperidyl) - aziHnofe\ 3':3,4JpyriOlo [1,2-a)indole-4,7-dione carbamate This compound was prepared by the procedure described in Example 1. From 70 mg of mitomycin A and 200 mg of 3-methyl pipeline was obtained 46 mg (55% yield) of the desired product having a melting point of 75®-88°C (decomposition) and providing the following analysis: NMR (CDClj, TS): f <51 values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 0.85 (d,3), 1.102.15 (m,5) and 2.15-3.32 (m,4).
Example 3 (Comparative) 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8a-methoxy5^methyl-6-(l-piperazinyiy-flizirinot^1,3^;3,4ipyrrolo-" [1,2-aJindole-4,7-dione carbamate This compound was prepared by the procedure described in Example 1. From 60 mg of mitomycin A and 30 mg of anhydrous piperazine was obtained 23 mg (34% yield) of the desired product having a melting point greater than 200°C (decomposition) and providing the following analysis: NMR (DMSO-d,, TS): *6' values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 1.9 (broad s,l) and 2.9 (s,8) .
Example 4 20 1,1a,2,8,8a,8b-ttexahydro-8-(hydroxymethyl)-8a-methoxy5-methyl-6-[4-(acetylamino)anilino]-azirinoT21,3':3,4] pyrrolo[1,2-afIndole-4,7-dione carbamate This compound was prepared by the procedure described in Example 1. From 100 mg of mitomycin A and excess 4-(acetylamino)aniline was obtained 102 mg (76% yield) of the desired product having a melting point of 143e-145eC (decomposition) and providing the following analysis: i 2 NMR (CDCI3, TS): 'δ* values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 2.1 (s,3), 7.4 (d,2), 7.6 (s,l) and 8.9-9.3 (s,l).
Example 5 1,la,2,8,8a,8b-Hexahvdro-8-(hydroxymethyl)-8a-methoxy5^methyl-6-[3-(acetylamino)aniflno]-azirino[2 *,31;3,4T pyrrolojl,2-a]indole^?, 7-dione carbamate This compound was prepared by the procedure described in Example 1, except that a small amount of solid potassium carbonate was added. From 70 mg of mitomycin A and 150 mg of 3-(acetylamino)aniline was obtained 67 mg (72% yield) of the desired product having a melting point of 140°-143°C (decomposition) and providing the following analysis: NMR (Acetone-dg, TS): ’δ1 values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 2.1 (s,3), 6.7-7.5 (m,4), 8.0 (broad s,l) and 9.3 (s,l), Example 6 1, la, 2,8,8a,8b-Hexahvdro-8-(hydroxymethyl)-8a-methoxyy-methyl-6-(4-acetylanilino)-azirino[21,31:3,4]pyrrolo [1,2-a]indoTe-4,7-dione carbamate This compound was prepared by the procedure described in Example 1, except that a small amount of solid potassium carbonate was added. From 70 mg of mitomycin A and 510 mg of 4-acetylaniline was obtained 25 mg (28% yield) of the desired product having a melting point of 103°-104eC (decomposition) and providing the following analysis: 3 NMR (CDCl^r TS): ’4' values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 2.1 (s,3), 6.6(d,2), 7.3 (d,2) and 7.0-7.3 (broad s,l).
Example 7 1,la,2,8,8a,8b-Hexahvdro-8-(hydroxytnethy 1)-8a-methoxy-5methyl-6~[4-(1-ureido)anllino]-azlrinot21,31: 3,4]pyrrolo [Ϊ,2-a]indole-4,7-dione carbamate This carbamido-substituted compound was prepared by the procedure described in Example 1. From 50 mg of mitomycin A and 227 mg of 4-(1-ureido)aniline was obtained 49 mg (67% yield) of the desired product having a melting point of 93®-95®C (decomposition) and providing the following analysis: NMR (CDClTS): ’o' values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 5.03 (s,2), 6.9 Example 8 20 1»la,2,8,8a,8b-Hexahydro-8-(hydroxytnethy 1) -8a-methoxy-5^ methyl-6-(4-cyanoaniiino)-azirino[21,3*:3,4]pyrrolofl,2-a] indole-4,7-dione^arbamate This compound was prepared by the procedure described in Example 1, except that a small amount of solid potassium carbonate was added. From 70 mg of mitomycin a and 472 mg of 4-aminobenzonitrile was obtained 23 mg (24% yield) of the desired product having a melting point of 124®-126®C (decomposition) and providing the following analysis: 4 NMR (CDCl^, TS): 'δ1 values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 6.6 (d,2), 7.4 (d,2) and 7.0-7.3 (broad s,l).
Example 9 1,la,2,8,8a,8b-Hexahvdro-8-(hydroxymethyl)-8a-methoxy-5methy1-6-(3-cyanoanilinoj-azlrino[21,31:3,4]pyrrolo[1,2-a] indole-4,7-dione carbamate This compound was prepared by the procedure described in Example 1, except that a small amount of solid potassium carbonate was added. From 71 mg of mitomycin A and 500 mg of 3-aminobensonitrile was obtained 30 mg (34% yield) of the desired product having a melting point of 97°-98°C (decomposition) and providing the following analysis: NMR (CDCl^, TS): '5* values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 7.2-7.8 (m,4).
Example 10 20 1*laf 2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8a-methoxy-5methyl-6-T4^(N-glycyl)anilino]-azirino[21,31:3,4)pyrrolo [1,2-a]xndole-4, T-3ione carbamate This compound was prepared by the procedure described in Example 1. From 50 mg of mitomycin A and 249 mg of 4-(N-glycyl)aniline was obtained 62 mg (90% yield) of the desired product having a melting point of 83®-85eC (decomposition) and providing the following analysis: NMR (DMSO-dg, TS): 'δ* values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 3.1 (s,2), 6.3-6.6 (broad s,2), 6.6-6.8 (broad s,2) and 6.6-7.1 (broad s,2).
Example 11 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8a-methoxy-5methvl-6-(3,4-dimethoxyanlllno)-azirino[21,31:3,4]pyrrolo Tl, 2-ίΐΤΐηάοΐ6-4,7-dione carbamate This compound was prepared by the procedure described in Example 1. From 50 mg of mitomycin A and 229 mg of 3,4-dimethoxyaniline was obtained 61 mg (91% yield) of the desired product having a melting point of 114°116 ®C (decomposition) and providing the following analysis: NMR (CDC13, TS): 'δ1 values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 3.8 (s,6), 6.3-6.9 (m,3) and 7.7 (s,l) .
Example 12 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8a-methoxy-5methyT-y- (3T5-dimethoxyaifiTino HazIrinoT21,3 r: 3,4ΓρντΓθ1ο (ΐ,2-a]indole-4,7-dione carbamate This compound was prepared by the procedure described in Example 1. - From 50 mg of mitomycin A and 229 mg of 3,5-dimethoxyaniline was obtained 60 mg (88% yield) of the desired product having a melting point of 98*-100*C (decomposition) and providing the following analysis: NMR (CDC13, TS): ’δ’ values in ppm.
Absence of the 6-methoxy peak at 4.02 and the 6 appearance of new peaks at 3.8 (s,6), 5.9-6.4 (broad s,3) and 7.6 (s,l).
Example 13 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8a-methoxy-5methyl-β- (4-nitgoaniiIno) -azirino_[21,31 ; 3,4] pyrrolo [1,2-a] indole-4,7-dione carbamate This compound was prepared by the procedure described in Example 1, except that a small amount of solid potassium carbonate was added. From 70 mg of mitomycin A and 276 mg of 4-nitroaniline was obtained 16 mg (9% yield) of the desired product having a melting point of 132°-134® C (decomposition) and providing the following analysis: NMR (Acetone-dg, TS): '6* values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 6.9-7.3 (d,2), 7.4-7.9 (d,2) and 7.9-8.4 (broad s,l).
Example 14 1,la,2,8,8 a,8b-Hexahydro-8-(hydroxymethyl)-8a-methoxy-5methvl-6- {4-sul£amoy3.anilinoy-azirino [21, 3 *: 3,4) pyrrolo [1,2-a)indole-4,7-dione carbamate This compound was prepared by the procedure described in Example 1, except that a small amount of solid potassium carbonate was added. From 70 mg of mitomycin A and 688 mg of sulfanilamide was obtained 25 mg (26% yield) of the desired product having a melting point of 113e-115eC (decomposition) and providing the following analysis: NMR (CDCl^, TS): *6’ values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 7.0 (d,2), 7.5 (s,l) and 7.9 (d,2).
Example 15 1,1al2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8a-methoxy-5methyl-6-(4-methylanilino)-azirinof 21, 3^ :3,4)pyrroloI1, 2-a) indole-4,7-dione carbamate This compound was prepared by the procedure described in Example 1. From 60 mg of mitomycin A and excess 4-methylaniline was obtained 63 mg (86% yield) of the desired product having a melting point of 113®115°C (decomposition) and providing the following analysis: NMR (CDCl^, TS)s ·$' values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 2.3 (s,3), 6.5-7.3 (broad s,4) and 7.6 (broad s,l).
Example 16 1,la,2,8,8a,8b-Hexahvdro-8-(hydroxymethyl)-8a-methoxy-5methyl-6-(3-methyranilino)^azirinol21,31:3,4]pyrrolo[1,2-a] indole-4,7-dione calrbamate This compound was prepared by the procedure described in Example 1. From 70 mg of mitomycin A and 276 mg of 3-methylaniline was obtained 66 mg (78% yield) of the desired product having a melting point of 89°-91°C (decomposition) and providing the following analysis: NMR (CDCl^, TS): 'δ * values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 2.4 (s,3), 6.7-7.5 (m,4) and 7.8 (s,l).
Example 17 1,1a,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8a-m6thoxy°5methyl-6-[(5-amino-l,2,4°triazol-3-yl)amino]-azirino (21,31:3,4)pyrrolo fl,2-a)indole-4,7-dione^carbamate This compound was prepared by the procedure described in Example 1, except that a small amount of solid potassium carbonate was added. From 50 mg of mitomycin A and 30 mg of 3,5-diamino-l,2,4-triazole was obtained 13 mg (5.5% yield) of the desired product having a melting point of 117°-120®C (decomposition) and providing the following analysis: NMR (DMSO-dg, TS): *6 * values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of a new peak at 5.37 (s,3).
Example 18 1.,la,2,8,8a,8b7Hexahydro-8-(hydroxymethyl)-8a-methoxy-5niethyl-6- {(3-i^thylis0thi~azol-5-yl) amino] -azirino (2 1,31:3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate This compound was prepared by the procedure described in Example 1, except that 0.5 ml of triethylamine was added. From 60 mg of mitomycin A and 30 mg of 5amino-3-methylisothiazole hydrochloride was obtained 4.5 mg (8.5% yield) of the desired product having a melting point of 87°-90eC (decomposition) and providing the following analysis: NMR (CDCl^r TS): ’6' values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 2.3 (s,3), 6.1 25 (s,l) and 6.4 (s,l).
Example 19 1,la,2,8,8a,8b-Hexahvdro-8-(hydroxymethyl)-8a-methoxy-5methy1-6-[(2-Fenzothiazoiyl) amino]-aziruno[ 2 *, 31: J, 4]pyrrolo Tl,2-a]indole-4,7-dione carbamate This compound was prepared by the procedure described in Example 1, except that a small amount of solid potassium carbonate was added. From 50 mg of mitomycin Ά and 25 mg of 2-aminobenzothiazole was obtained 12 mg (18% yield) of the desired product having a melting point of 82°-85’C [decomposition) and providing the following analysis: NMR (CDCl^, TS): '6' values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 7.1-8.0 (m,5).
Example 20 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)~8a-methoxy5-methyl-6-[(6-nitrobenzothiazol°2-yl)amino]-azirino [21,31;3,4) pyrrolo(1,2-a]indole-4,7-dione carbamate ‘ This compound was prepared by the procedure described in Example 1, except that a small amount of solid potassium carbonate was added. From 50 mg of mitomycin A and 30 mg of 2-amino-6-nitrobenzothiazole was obtained 20 mg (27% yield) of the desired product having a melting point of 869-89°C (decomposition) and providing the following analysis: NMR (DMSO-dg, TS): '6' values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 6.9-8.3 (m,4).
Example 21 1,1a,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8a-methoxy-5methvl-6-t(4-chlorobenzothiazol-2-yl)amino]-azirino [21 ® 3f 41 pyrroFo [37L2-a] indole-4,7/dione carbamate This compound was prepared by the procedure described in Example 1, except that a small amount of solid potassium carbonate was added. From 150 mg of mitomycin A and 27 mg of 2-amino-chlorobenzothiazole was obtained 30 mg (14% yield) of the desired product having a melting point of 89°-91°C (decomposition) and providing the following analysis: NMR (CDCl^, TS) s ’δ1 values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 7.1-8.0 (broad s,4) .
Example 22 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8a-methoxy-5methyl-6- [ (2-aminoethyi) amino] -azirino [ 21,311:3,4] pyrrolo [1,2-a]indole-4,7-dione carbamate This compound was prepared by the procedure described in Example 1, except that the solvent was dichloromethane. From 50 mg of mitomycin A and 10 mg of 1,2-diaminoethane was obtained 35 mg (65% yield) of the desired product having a melting point of 202®205®C (decomposition) and providing the following analysis: NMR (CDC13, TS) : ‘6 * values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 1.5 (broad s,2) and 3.5 (broad s,4).
Example 23 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8a-methoxy-5methvl-6-[methyl(2-methylaminoethyl)amino]-azlrino [2 *, 3^3,4] pyrrolo [ΪΤ2-a] indole-4*, 7-dione carbamate This compound was prepared by the procedure described in Example 1, except that a small amount of solid potassium carbonate was added. From 50 mg of mitomycin A and 25 mg of sym-dimethylethylenediamine was obtained 28 mg (50% yield) of the desired product having a melting point of 99-101°C (decomposition) and providing the following analysis: NMR (CDC13# TS)i *6’ values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 1.3 (s,l), 2.5 (s,6), and 2.7 (s,4).
Example 24 1,la,2,8,8a,8b-Hexahvdro-8-(hydroxymethyl)-8a-methoxy-5methyl-6-[2-(2-hydroxyethylamino)ethylamino]-azirino 12*,3' s3,4]pyrrolotlr2-a]indole-4,7-dione carbamate This compound was prepared by the procedure described in Example 1, except that the solvent was dichloromethane. From 50 mg of mitomycin A and 18 mg of 2-(2-aminoethylamino)ethanol was obtained 35 mg (58% yield) of the desired product having a melting point of 115°-118°C (decomposition) and providing the following analysis: NMR (CDCl^, TS): '6' values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 2.7 (broad s,7) and 3.7 (t,3).
Example 25 1, la, 2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8a-methoxv-5methyl-6- [2- (2-hydroxyethqxyJethy^aminol-azirino [21/31;3,4] pyrrolo [1,2-a] indole-4,7-clione carbamate This compound was prepared by the procedure described in Example 1, except that the solvent was dichloromethane. From 60 mg of mitomycin A and 20 mg of 2-(2-arainoethoxy)ethanol was obtained 30 mg (42% yield) of the desired product having a melting point of 99°-102°C (decomposition) and providing the following analysis: NMR (CDCl^r TS): values in ppmAbsence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 3.3-3.9 (broad s,9) and 6.4-6.8 (broad s,l).
Example 26 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8a-methoxy-5methyl-6- [ 2- 1 :TTU pyrrolo[1/2-a]indole-4T7-dione carbamate This compound was prepared by the procedure described in Example 1, except that 128 mg of sodium methoxide was added. From 70 mg of mitomycin A and 368 mg of histamine dihydrochloride was obtained 61 mg (71% yield) of the desired product having a melting point of 72°-73eC (decomposition) and providing the following analysis: NMR (DMSO-dg, TS): *6’ values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 3.0-3.27 (m,4), 7.5 (s,l), 8.0-8.7 (broad s,2) and 8.1 (s,l).
Example 27 1/la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8a-methoxy-5me thy1-6-ΐ(2-ni tro-1-imidaz oly 1)ethy1amino)-aziri no [2*,3f:3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate This compound was prepared by the procedure described in Example 1. From 72 mg of mitomycin A and excess 1-(2-aminoethyl)-2-nitroimidasole was obtained 60 mg (70% yield) of the desired product having a melting point of 83®-85°C (decomposition) and providing the following analysis: NMR (CDCl^f TS): ’δ1 values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 3.4 (t,2), 4.6 (t,2), 7.3 (broad s,2) and 7.6 (s,l).
Example 28 1, la,2,8,8a,8b-Hexahvdro-8°(hydroxymethyl)-8a-methoxy-55 methvl-6-12- (4-hydroxyphenyij ethylamino] -azlrino[2 r,~3 Γ:~3,4 3 pyrrolo[1,2-a]indoie-4,7-dlone carbamate This compound was prepared by the procedure described in Example 1. From 130 mg of mitomycin A and 510 mg of tyramine was obtained 138 mg (81% yield) of 10 the desired product having a melting point of 120°125*C (decomposition) and providing the following analysis: NMR (CDClj, TS): '6' values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 2.6 (t,2), 2.8 (t,2), 6.7 (d,2), 7.0 (d,2) and 8.0 (s,l).
Example 29 1,1a ,.2,8,8a,8b-Hexahydro-8- (hydroxymethyl) -8a-methoxy-5methyl-6-[2- (3,4-dihydroxyphenyl)ethylamino) -azirfno 20 f2f, P :3,4]pyrrolo (T, 2-a]in^ole-4,7-dione carbamate This compound was prepared by the procedure described in Example 1, except that 138 mg of sodium methoxide was added. From 110 mg of mitomycin A and 660 mg of 3-hydroxytyramine hydrobromide was obtained 60 mg (40% yield) of the desired product decomposing without melting above 125°C and providing the following analysis: NMR (CDCl^, TS): *6 * values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 2.6 (t,2), 2.8 (t,2), 6-4-6.8 (m,3) and 8.3 (broad s,2).
Example 30 1,la,2,8,8a,8b-Hexahvdro-8-(hydroxymethyl)-8a^methoxy-5methyl-6-{2-[(5-nitro-2-pyridyl)amxnoTethylamino)-azirino [21,3':3,4]pyrroio[1,2-a]indole-4,7-dione carbamate This compound was prepared by the procedure described in Example 1, except that the solvent was dichlorornethane. From 50 mg of mitomycin A and 30 mg of 2-(2-aminoethylamino)-5-nitropyridine was obtained 40 mg (56% yield) of the desired product having a melting point of 76*-79°C (decomposition) and providing the following analysis: NMR (CDCl^, TS): *61 values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 3.3-4.0 (m,4), 6.2-6.7 (broad s,2), 8.1 (d,l), 8.2 (d,l) and 9.0 (s,l).
Example 31 1,la,2,8,8a,8b-Hexahvdro-8-(hydroxymethyl)-8a-methoxy-5methyl-6-[2-(1-piperazinyl)ethylamino]-azirino t21,33,4] pyrroloTi »2-a]indole-4,7-dione*carbamate This compound was prepared by the procedure described in Example 1, except that the solvent was dichlorornethane. From 50 mg of mitomycin A and 20 mg of N-(2-aminoethyl) piperazine was obtained 23 mg (36% yield) of the desired product having a melting point of 138®-141®C (decomposition) and providing the following analysis: NMR (CDCl^r TS): '6' values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 1.6-2.1 (broad s,l), 2.2-2.6 (broad s,8), 2.6-2.8 (broad s,4) and 6.9 (t,l) .
Example 32 1, la, 2,8,8a, 8b-Hexahvdro-8- (hydroxymethyl) -8a-methoxy-5methyl-6-[2-(2-pyridyl)ethylamino]-azirino(21,31:3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate This compound was prepared by the procedure described in Example 1. From 70 mg of mitomycin A and 250 mg excess of 2-(2-aminoethyl)pyridine was obtained 51 mg (56% yield) of the desired product having a melting point of 64*-77°C (decomposition) and providing the following analysis: NMR (CDCl^, TS): '6' values in ppm.
Absence of the 6-methoxy peak at 4.02 and the appearance of new peaks at 2.8 (m,4), 7.0-7.8 (m,3) and 8.5 (d,l).
With specific reference to the compounds comprehended by formula Ilia, the above examples illustrate the following structural variations. 1. Compounds wherein Z is a hydroxy substituted 1-pyrrolidinyl radical represented by Example 1. 2. Compounds wherein Z is a lower alkyl substituted piperidyl radical represented by Example 2. 3. Compounds wherein z is an acetamino, acetyl, carbamido, cyano, carboxy lower alkylamino, di-lower alkoxy, nitro, sulfamyl or lower alkyl substituted anilino radical are represented, respectively, by Examples 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16. 4. Compounds wherein Z is a radical of the formula R -i-R^ and wherein is a nitrogen containing heterocylic radical selected from amino substituted triasolyl, lower alkyl substituted isothiazolyl, benzothiazolyl and nitro and halo substituted derivatives of benzothiazolyl are represented, respectively, by Examples 17, 18, 19, 20 and 21.
. Compounds wherein Z is a radical of the formula R -N-R^ and wherein R^ is a substituted lower alkyl radical selected from amino lower alkyl, lower alkylamino lower alkyl, hydroxy lower alkylamino lower alkyl, hydroxy lower alkoxy lower alkyl, imidazolyl lower alkyl, nitro substituted imidazolyl lower alkyl, mono- and di-hydroxy phenyl lower alkyl, nitro substituted pyridylamino lower alkyl, piperazinyl lower alkyl and pyridyl ethyl are represented, respectively, by Examples 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 32.
While none of the foregoing Examples are illustrative of compounds wherein Y is other than hydrogen, compounds wherein ¥ is lower alkyl are nonetheless within the comprehension of the invention, reference being made to analogously substituted compounds of aforesaid U.S. Patent No. 4,268,676, co-pending patent application Serial No. 206,529 and Patent Specification No. 52956 Compounds according to the present invention are believed to possess anti-bacterial activity against gram-positive and gram-negative microorganisms in a manner similar to that observed for the naturally occurring mitomycins and are thus potentially useful as therapeutic agents in treating bacterial infections in humans and animals.
Usefulness of oanpounds of formula Ilia in the manufacture of medicaments for use in antlneoplastic therapeutic methods is demonstrated by the results of in vivo screening procedures wherein the compounds are administered in varying dosage amounts to mice in which a P388 leukemic condition is induced. The procedures were carried out according to Lymphocytic Leukemia P388 - Protocol 1.200", published in Cancer Chemotherapy Reports, Part 3, Vol. 3, No. 2, page 9 (September, 1972). Briefly put, the screening procedures involved administration of the test compound to CDF^ female mice previously infected with 10^ ascites cells implanted intraperitonealiy Test compounds were administered on the first day of testing only, and the animals were monitored for vitality, * inter alia> over a 35-day period.
Results of screening of compounds of Examples 1 through 32 are set forth in Table I below. Data given includes optimal dose (O.D."), i.e., that dosage in mg/kg of body weight of the animal at which the maximum therapeutic effects are consistently observed.
Also included is the median survival time (MST) expressed as the MST of the test animals compared to the MST of controls x 100 (% T/C). Within the context of the in vivo P388 procedure noted above, a % T/C value of 125 or greater indicates significant antineoplastic therapeutic activity. The lowest dose in mg/kg of body weight at which the 125% T/C value is obtained is known as the minimum effective dose (MED). These doses also are listed in Table I. It is worthy of note that the exceptionally high MST values obtained in the P388 screenings reported in Table I are also indicative of the absence of substantial toxicity of the compounds at the dosages indicated.
TABLE 1 Example NO. Optimal Dose mg/kg MST as % T/C MED 1 25.6 163 0.8 2 25.6 238 <0.2 3 12.8 200 0.2 4 25.6 >333 <0.2 5 25.6 231 0.2 6 6.4 167 0.4 7 25.6 194 1.6 8 3.2 150 0.8 9 12.8 172 <0.2 10 25.6 322 0.8 11 12.8 >333 0.2 12 6.4 161 0.4 13 3.2 172 >0.2 14 25.6 225 0.2 15 12.8 167 0.4 16 12.8 181 0.4 17 12.8 181 1.6 18 25.6 169 0.8 19 25.6 150 12.8 20 25.6 128 25.6 21 25.6 144 1.6 22 3.2 178 0.4 23 25.6 133 12.8 24 12.8 133 12.8 25 25.6 181 0.4 26 25.6 163 1.6 27 25.6 150 3.2 28 25.6 218 1.6 29 12.8 139 12.8 30 12.8 144 6.4 31 25.6 138 12.8 32 25.6 >375 0.2 Clearly among the most preferred compounds employed as antineoplastic agents according to the invention are those exhibiting more than twice the relative life-extending capacity generally characterized as evidencing significant therapeutic potential, i.e., those having an MST % T/C value greater than 2 x 125.
The class of such compounds is seen to include the compounds of Examples 4, 10, 11 and 32.
As may be noted from Table X, initial single dosages of as little as 0.2 mg/kg showed substantial long term antineoplastic activity. Accordingly, the methods of treatment may involve therapeutic administra tion of unit dosages of as little as 0.001 mg or as much as 5 mg, preferably from 0.004 mg to 10 mg, of the compounds as the active ingredient in a suitable pharmaceutical preparation. Such preparations may be administered in a daily regimen calling for from 0.1 mg to 100 mg per kg, preferably from about 0.2 to about 51.2 mg per kg, of the body weight of the animal suffering from neoplastic disease. It is preferred that the compounds be administered parenterally. Pharmaceutical compositions suitable for use in practice of methods of the invention may comprise simple water solutions of one or more of the compounds of formula Ilia, but may also include well known pharmaceutically acceptable diluents, adjuvants and/or carriers such as saline suitable for medicinal use.
Further aspects and advantages of the present invention are expected to occur to those skilled in the 30 art upon consideration of the foregoing description and consequently only such limitations as appear in the appended claims should be placed thereon.

Claims (11)

1. CLAIMS;
1. A compound of the formula. wherein: Y is hydrogen or lower alkyl; and X is an hydroxy substituted 1-pyrrolidinyl radical, or a lower alkyl substituted piperidyl radical, or an acetamino, acetyl, carbamide, cyano, carboxy lower alkylamino, di-lower alkoxy, nitro, or sulfamoyl substituted anilino radical, or R a radical of the formula, -Ij-R^ wherein R is hydrogen or lower alkyl and R 1 is a nitrogen containing heterocyclic radical selected from amino substituted triazolyl, lower alkyl substituted isothiazolyl, benzothiazolyl, and nitro and halo substituted derivatives of benzothiazolyl, or R 1 is a substituted lower alkyl radical selected from amino lower alkyl, lower alkylamino lower alkyl, hydroxy lower alkylamino lower alkyl, hydroxy lower alkoxy lower alkyl, imidazolyl lower alkyl, nitro substituted imidazolyl lower alkyl, mono- and di-hydroxy phenyl lower alkyl, nitro substituted pyridylamino lower alkyl, and piperazinyl lower alkyl.
2. A compound according to Claim 1 selected from: 1, la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-Same thoxy-5-me thy 1-6- (3-hydroxy-l-pyrrolidinyl) -azirino [2 1 ,3':3,4]pyrrolo(1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-(3-methylpiperidyl)-azirino[2' ,3' :3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate ? 1,1a,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl6-[4-(acetylamino)anilino]-azirino [2 1 ,3':3,4]pyrrolo(1,2-a]indole-4,7-dione carbamate; 1,1a,2,8,8a,8b-Hexahydro-8- (hydroxymethyl)-8amethoxy-5-methyl-6-[3-(acetylamino)anilino]-azirino [2 1 ,3':3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-(4-acetylanilino)-azirino[2 1 ,3 1 :3,4] pyrrolo[1,2-aJ indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-Same thoxy-5-methyl-6- [4- (1-ureido)anilino]-azirino[2 1 ,3’:3,4] pyrrolo(1,2-a) indole-4,7-dione carbamate ? 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-(4-cyanoanilino)-azirino(2 1 ,3 1 :3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-(3-cyanoanilino)-azirino[2’,3':3,4] pyrrolo[1,2-a)indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-[4-(N-glycyl)anilino]-azirino[2’, 3’:3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-(3,4-dimethoxyanilino)-azirino[2 v ,3 f :3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-(3,5-dimethoxyanilino)-azirino[2 1 ,3’:3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-(4-nitroanilino)-azirino[2’,3’:3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-(4-sulfamoylanilino)-azirino[2', 3';3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,18,2,8,83,8b-Hexahydror8-(hydroxymethyl)-8amethoxy-5-methyl-6-[(5-amino-l,2,4-triazol-3-yl)amino]azirino[2',3’:3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methy1-6-[(3-methylisothiazol-5-yl)amino)-azirino [2 1 ,3':3,4]pyrrolo(1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-[(2-benzothiazolyl)amino]-azirino 12’,3 1 :3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,1a,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8a-methoxy5-methyl-6-[(6-nitrobenzothiazol-2-yl)amino)-azirino [2*,3’:3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl) 8a-methoxy-5-methyl-6-[(4-chlorobenzothiazol-2-yl) amino]azirino[2 1 ,3 1 :3,4]pyrrolo [1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-[(2-aminoethyl)amino]-azirino[2',3',3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-[methyl(2-methylaminoethyl)amino]-azirino [2',3':3,4]pyrrolo[l,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-Same thoxy-5-methyl-6- [2- (2-hydroxyethylamino)ethylamino]azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate? 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-[2-(2-hydroxyethoxy)ethylamino]-azirino [2',3*:3,4]pyrrolo[l,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-[2-(4-imidazolyl)ethylamino]-azirino [2*,3’:3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-[(2-nitro-l-imidazolyl)ethylamino]azirino[2 1 ,3 1 :3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate; 1, la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-[2-(4-hydroxyphenyl)ethylamino]-azirino [2',3':3,4]pyrrolo[l,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8a5 methoxy-5-methyl-6- [2-(3,4-dihydroxyphenyl)ethylamino]azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate? 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-{2-[(5-nitro-2-pyridyl)amino]ethylamino} azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate; 10 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-[2-(1-piperazinyl)ethylamino]-azirino [2*,3’:3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate.
3. · A substance for use in the preparation of a 15 medicament for treatment of a neoplastic disease state in an animal, said substance comprising a therapeutically effective amount of a compound of the formula, wherein: Y is hydrogen or lower alkyl; and Z 20 is an hydroxy substituted 1-pyrrolidinyl radical, or a lower alkyl substituted piperidyl radical, or 2 5 an acetamino, acetyl, carbamido, cyano, carboxy lower alkylamino, dilower alkoxy, nitro, sulfamoyl, or lower alkyl substituted anilino radical, or 3^ R a radical of the formula, -N-R^ wherein R is hydrogen or lower alkyl and R 1 is a nitrogen containing heterocyclic radical selected from amino substituted triazolyl, lower alkyl substituted isothiazolyl, benzothiazolyl, and nitro and halo substituted derivatives of benzothia- * zolyl, or R 1 is a substituted lower alkyl radical selected from amino lower alkyl, lower * alkylamino lower alkyl, hydroxy lower alkylamino lower alkyl, hydroxy lower alkoxy lower alkyl, imidazolyl lower alkyl, nitro substituted imidazolyl lower alkyl, mono- and di-hydroxy phenyl lower alkyl, nitro substituted pvridylamino lower alkyl, piperazinyl lower alkyl, and 2-(pyridyl) ethyl.
4. A substance according to Claim. 3 wherein the compound is selected from: 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-(3-hydroxy-l-pyrrolidinyl)-azirino [2 1 ,3':3,4]pyrrolo(1,2-a)indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-S-(hydroxymethyl)-8amethoxy-5-methyl-6-(3-methylpiperidyl)-azirino[2’,3’:3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate? 1, la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-[4-(acetylamino)anilino]-azirino [2^3 1 :3,4]pyrrolo[ 1,2-a] indole-4,7-dione carbamate; 1,la,2,8,8a,3b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-[3-(acetylamino)anilino]-azirino [2^,3 1 :3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate ? * 1, la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-3amethoxy-5-methyl-6-(4-acetylanilino)-azirino[2',3 1 :3,4] T pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,1a,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-(4-(1-ureido)anilino]-azirino[2 1 ,3 1 :3,4) pyrrolo(1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6- (4-cyanoanilino)-azirino[2 ^3^3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate ? 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6- (3-cyanoanilino) -azirino [2^3^3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-eame thoxy -5-me thy 1-6- [4-(N-glycyl)anilino]-azirino[2 1 ,3 1 :3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate? 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6- (3,4-dimethoxyanilino)-azirino[2 1 ,3*:3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-(3,5-dimethoxyanilino)-azirino[2 *,3 1 :3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate ? 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6- (4-nitroanilino)-azirino[2’,3’:3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-(4-sulfamoyl anilino)-azirino(2’,3 * :3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-(4-methylanilino)-azirino[2 1 ,3':3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-(3-methylanilino)-azirinoI2 1 ,3':3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl) -8amethoxy-5-methyl-6-[(5-amino-l,2,4-triazol-3-yl) amino]azirino[2',3 1 :3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6- [ (3-methylisothiazol-5-yl)amino]-azirino [2',3':3,4]pyrrolo(1,2-a]indole-4,7-dione carbamate? 1, la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)8a-methoxy-5-methyl-6-[(2-benzothiazolyl)amino]-azirino [2*,3’:3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate? 1,la,2,8,8a,8b-Hexahyaro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-I(6-nitrobenzothiazol-2-yl)amino]-azirino (2’,3’:3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate? t 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-((4-chlorobenzothiazol-2-yl)amino]azirino[2*,3 1 :3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate; ‘ 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-[(2-aminoethyl)amino]-azirino(2',3':3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-Same thoxy-5-methyl-6- [methyl (2-methylaminoethyl) amino]-azirino [2 1 ,3’:3,4]pyrrolo[l,2-a]indole-4,7-dione carbamate? 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-(2-(2-hydroxyethylamino)ethylamino]azirino [2’,3 1 :3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate; 1, la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methy1-6-[2-(2-hydroxyethoxy)ethylamino]-azirino [2 1 ,3’:3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methy1-6-[2-(4-imidazolyl)ethylamino]-azirino [2’,3’:3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-[(2-nitro-l-imidazolyl)ethylamino]azirino [2',3 β 23,4] pyrrolo [ 1,2-a] indole-4,7-dione carbamate; 1, la, 2,8,8a, 8b-Hexahydro-8- (hydroxymethyl) -Same thoxy-5-methyl-6- t2-(4-hydroxyphenyl)ethylamino]-azirino [2*,3':3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate; 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-eame thoxy-5-me thy 1-6- [2-(3,4-dihydroxyphenyl)ethylamino]azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate; » 1,la,2,8,8a,8b-Hexahydro-8-(hydroxymethyl)-8amethoxy-5-methyl-6-{2-[(5-nitro-2-pyridyl)amino]ethylamino)azirino[2',3 1 :3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate ? 1,la,2,8,8a,8b-Hexahydro-8- (hydroxymethyl) -8amethoxy-5-methyl-6- [2- (2-pyridyl)ethylamino] -asirino [2' ,3' :3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate. j 5. A substance according to claim 3 wherein the amount
5. Of the compound administered comprises a daily dose of from 0.2 mg to 51.2 mg per kg of the body weight of the animal.
6. A pharmaceutical composition for use in treatment of a neoplastic disease in an animal, said 10 composition comprising a pharmaceutically acceptable solvent, diluent, adjuvant or carrier and, as the active ingredient, from 0.001 to 5 mg of a compound of the formula 15 wherein: Y is hydrogen or lower alkyl; and Z is an hydroxy substituted 1-pyrrolidinyl radical, or a lower alkyl substituted piperidyl radical, 20 or an acetamino, acetyl, carbamido, cyano, carboxy lower alkylamino, di7 lower alkoxy, nitro, sulfamoyl, or lower alkyl substituted anilino radical, or R a radical of the formula, -N-R^ wherein R is hydrogen or lower alkyl and R 1 is a nitrogen containing heterocyclic radical selected from amino substituted triazolyl, lower alkyl substituted isothiazolyl, benzothiazolyl, and nitro, and halo substituted derivatives of benzothiazolyl, or r1 is a substituted lower alkyl radical selected from amino lower alkyl, lower alkylamino lower alkyl, hydroxy lower alkylamino lower alkyl, hydroxy lower alkoxy lower alkyl, imidazolyl lower alkyl, nitro substituted imidazolyl lower alkyl, mono- and di-hydroxy phenyl lower alkyl, nitro substituted pyridylamino lower alkyl, piperazinyl lower alkyl, and 2-(pyridyl)ethyl.
7. A compound of the formula (III) given and defined in Claim 1, which is any one of those specifically hereinbefore mentioned, other than those claimed in Claim 2.
8. A process for preparing a compound of the formula (III) given and defined in Claim 1, substantially as hereinbefore described vzith particular reference to the accompanying Examples.
9. A compound of the formula (III) given and defined in Claim 1, whenever prepared by a process claimed in Claim 8.
10. A substance according to Claim 3, substantially as hereinbefore described.
11. A pharmaceutical composition according to Claim 6, substantially as hereinbefore described.
IE272/84A 1983-02-07 1984-02-06 Mitomycin analogs IE56814B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46461283A 1983-02-07 1983-02-07

Publications (2)

Publication Number Publication Date
IE840272L IE840272L (en) 1984-08-07
IE56814B1 true IE56814B1 (en) 1991-12-18

Family

ID=23844605

Family Applications (1)

Application Number Title Priority Date Filing Date
IE272/84A IE56814B1 (en) 1983-02-07 1984-02-06 Mitomycin analogs

Country Status (29)

Country Link
JP (1) JPS59152384A (en)
KR (1) KR900006854B1 (en)
AT (1) AT385509B (en)
AU (1) AU571193B2 (en)
BE (1) BE898856A (en)
CA (1) CA1252789A (en)
CH (1) CH658658A5 (en)
DD (1) DD233844A5 (en)
DE (1) DE3403922A1 (en)
DK (1) DK161890C (en)
ES (1) ES8607305A1 (en)
FI (1) FI80698C (en)
FR (1) FR2540500B1 (en)
GB (1) GB2134514B (en)
GR (1) GR81455B (en)
HU (1) HU190236B (en)
IE (1) IE56814B1 (en)
IL (1) IL70897A (en)
IT (1) IT1178855B (en)
LU (1) LU85199A1 (en)
NL (1) NL8400338A (en)
NO (1) NO161374C (en)
NZ (1) NZ206932A (en)
OA (1) OA07654A (en)
PH (1) PH20249A (en)
PT (1) PT78067B (en)
SE (1) SE461982B (en)
YU (1) YU44984B (en)
ZA (1) ZA84788B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4487769A (en) * 1982-06-04 1984-12-11 Bristol-Myers Company Amidines
CA1282069C (en) * 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
JPS63150282A (en) * 1986-12-13 1988-06-22 Kyowa Hakko Kogyo Co Ltd Mitomycin derivative
JPS63246379A (en) * 1987-03-31 1988-10-13 Kyowa Hakko Kogyo Co Ltd 7-n,8-n-ethylenemitomycin 8-imines
DE69127345D1 (en) * 1990-11-13 1997-09-25 Kyowa Hakko Kogyo Kk Mitomycin derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3332944A (en) * 1964-11-02 1967-07-25 American Cyanamid Co Antibiotic derivatives of mitomycins a, b, c and porfiromycin
JPS5439098A (en) * 1977-08-31 1979-03-24 Kyowa Hakko Kogyo Co Ltd Mitomycin c derivatives
US4268676A (en) * 1979-12-05 1981-05-19 University Patents, Inc. Mitomycin analogs
JPS5686184A (en) * 1979-12-17 1981-07-13 Kyowa Hakko Kogyo Co Ltd Novel mitomycin c derivative
NZ199617A (en) * 1981-05-15 1985-08-30 University Patents Inc Azirino(2',3',:3,4)pyrrolo(1,2-a)indole-4,7-dione derivatives and pharmaceutical compositions
US4487769A (en) * 1982-06-04 1984-12-11 Bristol-Myers Company Amidines
US4642352A (en) * 1983-12-23 1987-02-10 Bristol-Myers Company Acylamino mitosanes

Also Published As

Publication number Publication date
ATA37684A (en) 1987-09-15
KR840007726A (en) 1984-12-10
DD233844A5 (en) 1986-03-12
NO161374C (en) 1989-08-09
GR81455B (en) 1984-12-11
ZA84788B (en) 1984-09-26
PT78067A (en) 1984-03-01
SE461982B (en) 1990-04-23
PH20249A (en) 1986-11-10
AU571193B2 (en) 1988-04-14
FI80698B (en) 1990-03-30
AT385509B (en) 1988-04-11
JPS59152384A (en) 1984-08-31
DK52484A (en) 1984-08-08
IL70897A (en) 1989-01-31
BE898856A (en) 1984-05-30
ES8607305A1 (en) 1986-05-16
FR2540500B1 (en) 1987-07-17
DK161890C (en) 1992-02-03
FI840502A (en) 1984-08-08
YU44984B (en) 1991-06-30
DK52484D0 (en) 1984-02-06
KR900006854B1 (en) 1990-09-22
LU85199A1 (en) 1984-05-30
FI840502A0 (en) 1984-02-07
IT1178855B (en) 1987-09-16
AU2407384A (en) 1984-08-16
PT78067B (en) 1986-03-20
DK161890B (en) 1991-08-26
SE8400628D0 (en) 1984-02-07
HU190236B (en) 1986-08-28
CA1252789A (en) 1989-04-18
ES529478A0 (en) 1986-05-16
IL70897A0 (en) 1984-05-31
IT8467113A0 (en) 1984-02-07
GB2134514B (en) 1987-04-01
NL8400338A (en) 1984-09-03
SE8400628L (en) 1984-08-08
IE840272L (en) 1984-08-07
YU21784A (en) 1986-10-31
GB2134514A (en) 1984-08-15
FR2540500A1 (en) 1984-08-10
NO161374B (en) 1989-05-02
CH658658A5 (en) 1986-11-28
NO840433L (en) 1984-08-08
OA07654A (en) 1985-05-23
NZ206932A (en) 1987-08-31
FI80698C (en) 1990-07-10
DE3403922A1 (en) 1984-08-09
GB8402233D0 (en) 1984-02-29

Similar Documents

Publication Publication Date Title
EP0800390B1 (en) Cyclopropylpyrroloindole-oligopeptide anticancer agents
US4268676A (en) Mitomycin analogs
US4746746A (en) Mitomycin analogs
CA1244412A (en) Mitomycin analogs
IE56814B1 (en) Mitomycin analogs
US5023253A (en) 6-substituted mitomycin analogs
US4617389A (en) Mitomycin analogs
US4460599A (en) Mitomycin analogs
GB2223753A (en) Piperazine derivatives
US4590074A (en) Bis-amidines
EP0443569A2 (en) Diamine derivatives and their use in oncology
SU1272993A3 (en) Method of producing mitomycin derivatives
US4579737A (en) Bis-amidines
CA1082188A (en) Azabicylic compounds, methods, and intermediates
US4885304A (en) Mitomycin analogs

Legal Events

Date Code Title Description
MM4A Patent lapsed